FoxWayne Enterprises Acquisition Corp. (NASDAQ:FOXW) announced this afternoon that it has agreed to mutually terminate its combination with biopharmaceutical company Aerami Therapeutics.
Similar to other recent SPAC terminations, FoxWayne has also stated that it will be terminating its combination due to unfavorable market conditions. The SPAC’s current extended deadline is April 22, 2022, but FoxWayne can extend an additional three months to July 22, 2022 by contributing $0.025 per share to trust. That gives this SPAC roughly 4.6 months left to complete a business combination, assuming they extend.
The FoxWayne/Aerami deal marks the ninth intended SPAC combination to terminate in 2022 year-to-date, and the third in the biotech/healthcare sector, which as a sector has been struggling. However, on average, those nine terminated deals still have 9.6 months of life left to find another combination and complete.
FoxWayne originally priced a $50 million IPO last January and intends to focus on combining with a biotechnology or telemedicine business in North America that will be resilient to economic cycles. The company is led by Chairman, CEO and CFO Robb Knie.
The SPAC originally announced its combination with Aerami a few months ago in the beginning of December. Durham, North Carolina-based Aerami is developing a series of inhaled therapies for severe respiratory diseases and inhaled insulin solutions.


Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...
At the SPAC of Dawn One of the biggest sources of uncertainty in the SPAC market in recent years has been regulatory changes, but new shifts could be in its favor. SEC Chairman Paul Atkins told CNBC yesterday that the commission would review the rules for SPACs after “rather controversial” changes to the rules passed...
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...